天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片
上海阿拉丁生化科技股份有限公司 Company Information
Company Name:
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel:
400-6206333
Email:
market@aladdin-e.com
Nationality:
China
WebSite:
www.aladdin-e.com/
Product List:
48461
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
Product List
Muromonab (anti-CD3)
140608-64-6
Mupadolimab (anti-CD73)
2451856-97-4
Amatuximab (anti-MSLN)
931402-35-6
Aducanumab (anti-APP)
1384260-65-4
Aprutumab (anti-FGFR2)
1634620-63-5
Anifrolumab (anti-IFNAR1)
1326232-46-5
Rovalpituzumab (anti-DLL3)
1613313-01-1
Simtuzumab (anti-LOXL2)
1318075-13-6
Lorvotuzumab (anti-CD56)
339306-30-8
Sifalimumab (anti-IFNa1)
1006877-41-3
Onvatilimab (anti-VISTA)
1969313-51-6
Ibalizumab (anti-CD4)
680188-33-4
Figitumumab (anti-IGF1R)
943453-46-1
Onartuzumab (anti-MET)
1133766-06-9
Belantamab (anti-TNFRSF17)
2061894-48-0
Erenumab (anti-CALCRL)
1582205-90-0
Omburtamab (anti-CD276)
1895083-75-6
Envafolimab (anti-PD-L1)
2102192-68-5
Oleclumab (anti-CD73)
1803176-05-7
Margetuximab (anti-HER2)
1350624-75-7
Talquetamab (anti-GPRC5D)
2226212-40-2
Varlilumab (anti-TNFRSF7)
1393344-72-3
Naxitamab (anti-GD2)
1879925-92-4
Cusatuzumab (anti-CD70)
1864871-20-4
Fletikumab (anti-IL-20)
1357158-22-5
Nadunolimab (anti-IL-1 RAcP)
2171061-85-9
Penpulimab (anti-PDCD1)
2350298-92-7
Fezakinumab (anti-IL-22)
1007106-86-6
Otelixizumab (anti-CD3)
881191-44-2
Sotigalimab (anti-CD40)
2305607-45-6
Zilovertamab (anti-ROR1)
2485779-13-1
Farletuzumab (anti-FOLR1)
896723-44-7
Selicrelumab (anti-CD40)
1622140-49-1
Teprotumumab (anti-IGF1R)
1036734-93-6
Blosozumab (anti-SOST)
1132758-87-2
Olokizumab (anti-IL-6)
1007223-17-7
Canakinumab (Anti-IL-1b)
914613-48-2
Etrolizumab (anti-α4β7)
1044758-60-2
Mavrilimumab (anti-CD116)
1085337-57-0
Sofituzumab (anti-MUC16)
1615692-28-8
Tregalizumab (anti-CD4)
1207446-68-1
Teplizumab (anti-CD3e)
876387-05-2
Bemarituzumab (anti-FGFR2)
1952272-74-0
Brentuximab (anti-TNFRSF8)
2088770-90-3
Eptinezumab (anti-CGRP)
1644539-04-7
Emicizumab (anti-Factor IX)
1610943-06-0
Patritumab (anti-ERBB3)
1262787-83-6
Motavizumab (anti-RSV-F)
677010-34-3
Mirvetuximab (anti-FOLR1)
1453084-36-0
Abituzumab (anti-ITGAV)
1105038-73-0
Zinc selenide
1315-09-9
Z-FA-FMK
197855-65-5
Zirconium acetate
7585-20-8
Zearalenone from Giberella zeae
17924-92-4
Zanamivir
139110-80-8
Zinc acetylacetonate hydrate
108503-47-5
Etokimab (anti-IL-33)
2022981-44-6
Tremelimumab (anti-CTLA-4)
745013-59-6
Denosumab (anti-TNFSF11)
615258-40-7
Sintilimab (anti-PD-1)
2072873-06-2
Zinc iron oxide
12063-19-3
Panitumumab (anti-EGFR)
339177-26-3
Sabatolimab (anti-TIM-3)
2252262-24-9
Mepolizumab (anti-IL-5)
196078-29-2
Sacituzumab (anti-TROP2)
1796566-95-4
Magrolimab (anti-CD47)
2169232-81-7
Vibostolimab (anti-TIGIT)
2231305-30-7
Relatlimab (anti-LAG-3/CD223)
1673516-98-7
Ofatumumab (anti-CD20)
679818-59-8
Zandelisib
1401436-95-0
Zoledronic Acid
118072-93-8
Spartalizumab (anti-PD-1)
1935694-88-4
Risankizumab (anti-IL-23)
1612838-76-2
Omalizumab (anti-IgE)
242138-07-4
ZM 39923 HCl
1021868-92-7
Zibotentan (ZD4054)
186497-07-4
Recombinant Human VEGF Protein
127464-60-2
Vedolizumab (anti-α4β7-integrin)
943609-66-3
Zalcitabine
7481-89-2
Tiragolumab (anti-TIGIT)
1918185-84-8
Brodalumab (anti-IL17RA)
1174395-19-7
Zebularine (NSC 309132)
3690-10-6
Isatuximab (anti-CD38)
1461640-62-9
Zafirlukast (ICI-204219)
107753-78-6
Evolocumab(anti-PCSK9)
1256937-27-5
Pamrevlumab (anti-CTGF)
946415-13-0
Emapalumab (anti-IFNγ)
1709815-23-5
Z-LEHD-FMK TFA
524746-03-0
Evinacumab (anti-ANGPTL3)
1446419-85-7
Zolantidine dimaleate
104076-39-3
Zoledronic Acid Disodium Salt Tetrahydrate
165800-07-7
Siltuximab (anti-IL-6)
541502-14-1
Necitumumab (anti-EGFR)
906805-06-9
Zolmitriptan
139264-17-8
Zileuton (A-64077)
111406-87-2
Zaltoprofen
74711-43-6
Zinc Pyrithione
13463-41-7
Zinc fluoborate hydrate
27860-83-9
Zirconium hydroxide
14475-63-9
ZM 306416
690206-97-4
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
Copyright 2007© ChemicalBook. All rights reserved.